Filing Flows › Onconetix (ONCO) › Q1 2026
Onconetix (ONCO) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 13, 2026
Onconetix (ONCO) reported revenue of $21K for the first quarter 2026 (Q1 2026), -79% from a year earlier and -93% from the quarter before.
Onconetix, Q1 2026: revenue $21K (-79% year over year), net loss $4.2M, operating cash flow −$2.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $21K | -93% | -79% |
| Operating profit | −$10.2M | — | — |
| Net earnings | −$4.2M | -174% | — |
| Operating cash flow | −$2.1M | — | — |
What changed
Revenue was $21K in Q1 2026, down 79% year over year and down 93% from the previous quarter.
Operating costs exceeded revenue by $10.2M, an operating margin of -47657.2%. The fastest-growing cost line was SG&A (+22%). The quarter ended with a net loss of $4.2M, after a profit of $5.7M the previous quarter. Non-operating items added $6.0M, -143% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$2.1M. Non-cash charges added back $5K of depreciation and amortization and $22K of share-based compensation. Working capital and other items added $2.1M.
Questions
What was Onconetix's revenue in the first quarter 2026?
Onconetix (ONCO) reported revenue of $21K for the first quarter 2026 (Q1 2026), -79% from a year earlier and -93% from the quarter before.
Source: Onconetix 10-Q on SEC EDGAR.